Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial

Opus Reports Vision Improvements for Three Pediatric Patients in Phase 1/2 Clinical Trial for LCA5 Gene Therapy

Eye on the Cure Podcast | Episode 92: Lance Baldo, MD

Agnes Gund – Renowned Philanthropist, Social Justice Champion, and Art Patron – Passes Away

Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial

Eye on the Cure Podcast | Episode 91: Dr. George Magrath

Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy

jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy

Eye on the Cure Podcast | Episode 90: Dr. Christina Ohnsman

Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial

Eye on the Cure Podcast | Episode 89: Dr. Christine Curcio

Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy

Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy

Eye on the Cure Podcast | Episode 88: Richard Small

Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort

Eye on the Cure Podcast | Episode 87: Dr. Philip Beales

Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD

J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial

ARVO 2025 Highlight: PYC Reports Encouraging Phase 1/2 Clinical Trial Results for its RNA Therapy Targeting RP (PRPF31 Mutations)

ARVO 2025 Highlight: Atsena’s XLRS Gene Therapy Provides Vision and Structural Improvements in Phase 1/2 Clinical Trial